Form 4: Black Diamond Therapeutics Director Acquires and Disposes of Shares

Director Prakash Raman acquired 2,694 shares and disposed of 4,995 shares of Black Diamond Therapeutics common stock on September 20, 2024.

Summary

• On September 20, 2024, Prakash Raman, a director of Black Diamond Therapeutics, engaged in transactions involving the company's common stock.
• Raman acquired 2,694 shares at a price of $4.78 per share.
• Simultaneously, Raman disposed of 4,995 shares.
• Following these transactions, Raman's beneficially owned shares totaled 4,995.
• The acquisition of shares was in lieu of cash compensation for annual services as a non-employee director, according to the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy.
• The price reported is based on the closing market price of the Issuer's common stock on September 19, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While a director acquired shares, they also disposed of a larger quantity. The acquisition was part of a compensation plan, which is a standard practice.

Positives

• The director's acquisition of shares, even if offset by a larger disposal, could be seen as a sign of confidence in the company's future, especially as it's linked to compensation.

Negatives

• The disposal of 4,995 shares by a director could be interpreted negatively by investors, regardless of the reason.

Risks

• The document does not explicitly state any risks, but the disposal of shares by a director could create uncertainty among investors.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The market will interpret the transactions based on the individual's role, the size of the transaction, and the overall context of the company's performance.

Stakeholder Impact

• Shareholders may react to the director's share disposal, potentially impacting the stock price.

Key Dates